Although predictive and experimental evidence suggests that ECH targets the TP53/SLC7A11/GPX4 pathway to promote ferroptosis and inhibit HCC progression, this study has several limitations. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.